TWI324062B - Composition for treating cancer cells and synthesis method thereof - Google Patents

Composition for treating cancer cells and synthesis method thereof Download PDF

Info

Publication number
TWI324062B
TWI324062B TW096112618A TW96112618A TWI324062B TW I324062 B TWI324062 B TW I324062B TW 096112618 A TW096112618 A TW 096112618A TW 96112618 A TW96112618 A TW 96112618A TW I324062 B TWI324062 B TW I324062B
Authority
TW
Taiwan
Prior art keywords
group
compound
flavonoid
composition
ring
Prior art date
Application number
TW096112618A
Other languages
English (en)
Other versions
TW200840561A (en
Inventor
An Shen Lin
Yang Chang Wu
Kuo Hsiung Lee
Fang Rong Chang
Original Assignee
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kaohsiung Medical filed Critical Univ Kaohsiung Medical
Priority to TW096112618A priority Critical patent/TWI324062B/zh
Priority to EP08006865.3A priority patent/EP1980248B1/en
Priority to HUE08006865A priority patent/HUE046349T2/hu
Priority to KR1020080031721A priority patent/KR20080092260A/ko
Priority to AU2008201553A priority patent/AU2008201553B2/en
Priority to JP2008101826A priority patent/JP5021549B2/ja
Publication of TW200840561A publication Critical patent/TW200840561A/zh
Application granted granted Critical
Publication of TWI324062B publication Critical patent/TWI324062B/zh
Priority to JP2011259177A priority patent/JP5547167B2/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

methyl ether)—滴一滴緩慢加入溶液。加熱迴流九十分鐘使其 反應,靜置後過濾出沈澱物,並以丙酮及氯仿沖洗沈殺物,^ 以正己完/乙酸乙g旨90/10的比例進行管柱層析,即可得到在 4’與6’位置上形成具有MOM保護基的2,_羥基_4,,6,_二甲氧 基苯乙酮(2,-hydroxy-4,,6,-dimeth〇XymethyI-acetoPhenone),^ 率為50.3%。 ^將前一步驟所得到的2,-經基-4,,6,-二甲氧基笨乙酮與4_ ¥ 氧基苯曱搭(4-benzyloxy-benzaldehyde)進行 Claisen-Schmidt 縮合反應(Claisen-Schmidt Condensation)。在含有 2,·羥基_4, 6,- 一曱氧基苯乙酮的乙醇溶液中加入2當量的4-节氧基苯甲 醛,攪拌後加入催化量的氫氧化鉀,室溫下攪拌小時後, 進行減壓濃縮以去除溶劑,再以正己烷/乙酸乙酯進行管柱層 析’即可得到第一化合物,產率為87.2%。 曰 將第一化合物溶解於適量吡啶之中,並加入0.2當量的 蛾。加熱迴流5小時後,加入硫代硫酸納並以乙酸以酯/水萃 取,有機層經減壓濃縮後以管柱層析分離可得到第二化合物, 產率為85.5%。 在’谷有弟一化合物的乙酸乙g旨/甲醇溶液中,加入1當量 的10 °/。碳纪,在氫氣的催化之下反應三小時,過濾除去碳絶 之後,將溶液進行減壓濃縮,即可得到第三化合物,產率為 88.9%。 ’” 第三化合物加入催化量的TEMPO後,在加熱的條件下以 1當量的二醋酸蛾苯(iodobenzene diacetate)或雙三氟乙酿氧填 化本[bis(trifluoroacetoxy)i〇do]benzene 進行氧化反應,得到一 反應產物a,將該反應產物a以乙酸乙|旨/水萃取,得到一有 機層萃取物’再將該有機層萃取物以反覆的管柱層析分離之後 即可得到第四化合物,產率為22.2%。 在酸的條件之下將第四化合物以濃鹽酸加熱脫去4,與6, 位置上的MOM保護基,即可得到pr〇t〇apigen〇ne,產率46 7〇/〇。 1324062 實施例二:化合物protoapigenone衍生物的丰合成方法 本實施例為以化學方法半合成化合物8a: protoflavonone (IIUPAC名稱為2-(1-羥基-4-酮基-2,5-環己二烯基)-4氫-色烯 -4-酮’ 2-(l-hydroxy-4-〇x〇cyclohexa-2,5-dienyl)-4H-chromen _4-one)、化合物 l〇a: 5-hydroxyprotoflavone (IIUPAC 名稱為 2-(1-羥基-4-酮基-2,5-環己二烯基)-5-羥基-4氫-色烯-4-酮, 2- (l-hydroxy-4-〇xocyclohexa-2,5-dienyl)-5-hydroxy-4H-chrome n-4-one)、化合物 15a: ;5-naphthoflavonone (IIUPAC 名稱為 3- (1-輕基-4-酮基-2,5-環己二烯基)-1氫-苯并[f]色烯小酮, 3 -(1 -hy droxy-4-oxocy clohexa-2,5 -dienyl)-1 H-benzo[f]chromen-1 -one)與化合物 18a · 5-hydroxy-7-methoxyprotoflavonone (IIUPAC名稱為5-羥基-2-(1-經基-4-酮基-2,5-環己二烯基)-7-曱 氧基-4 氫-色烯_4_酮 ’ 5-hydroxy-2-(l-hydroxy-4-〇x〇cyclohexa-2,5-dienyl)-7-methoxy-4H-chromen-4-one) ° 將市售的 基黃_(4f_hydroxyflavone)、4’_5-二經基黃 酮(4’-5-dihydroxyflavone)、4’-羥基-β 萘黃酮(4,_hydroxy_ β -naphthoflavone)與 4’,5-二羥基-7-甲氧基黃酮 (4、5-dihydroxy-7-methoxyflavone)溶於適量的水中,再分別加 # 入催化量的TEMPO後,在加熱的條件下以1當量的二醋酸埃 苯(iodobenzene diacetate)或雙三氟乙醯氧碘化苯 [bis(trifluoroacetoxy)iodo]benzene 進行氧化反應,得到一反應 產物b ’將該反應產物b以乙酸乙酯/水萃取,再將有機層萃取 物以反覆的管柱層析分離之後即可得到pr〇t〇f[av〇n〇en (化合 物 8a)、5-methylprotoflavonone (化合物 i〇a)、石 -naphthoflavonone .(化合物 15a)與 5-hydroxy-7_ methoxyprotoflavonone(化合物18a),結構變化如第二圖所示, 產率為20-30%。 在另一情況下’也可將市售的4,-羥基黃酮 11 (4’-1^(11'〇父3^[^〇116)、4’-5-二經基黃酮(4’-5-(1^以(11:〇又丫£^〇1^)、4,- 羥基-yS -萘黃酮(4f-hydroxy- /3 -naphthoflavone)與 4,,5-二羥基 -7-曱氧基黃酮(4\5-dihydroxy-7-methoxyflaVone)溶於適量的 曱醇中,再分別加入催化量的TEMPO後,在加熱的條件下以 1當量的二醋酸破苯(iodobenzene diacetate)或雙三氟乙酿氧峨 化苯[bis(trifluoroacetoxy)iodo]benzene 進行氧匕反應,得到一 反應產物c,將該反應產物c以乙酸乙酯/水萃取,再將有機層 萃取物以反覆的管柱層析分離之後即可得到在i,位置帶有曱 氧基團的 1 Lmethoxyprotoflavonone (化合物 、 l’-methoxy-5-methylprotoflavonone (化合物 l〇b)與 r-metiioxy-/5-naphthoflavonone (化合物15b),結構變化如第三圖所示, 產率為25-35 %。 實施例三:化合物pr〇t〇apigenone衍生物的生物活性 細胞組織培巷 人類肝癌細胞(HepG2、Hep3B)、乳癌細胞(MCF-7、 MDA-MB-231)、肺癌細胞(A549)培養於 minimal essential medium培養液中,其中含10%胎牛血清(fetal calf serum)及含 1^)0 u^its/ml盤尼西林與1〇〇 μ1/ιη1鏈徽素培養於5%二氧化 碳、3JC及含飽和^蒸氣之培養箱。每三天更換一次培養基溶 液,當長至培養瓶單層長滿(confluent)時便作轉殖。實驗期視 實驗目的,以灰球計數器計算細胞數目,再取適當細胞數目作 細胞毒殺試驗 以右MTT染色法可將活細胞内蛋白f染色,再 染色物質溶出,經由光學活性吸光值之檢測,進 95Γ==率。f5x103至ixiq4細胞種於96孔盤中,於 ° ·* 。一氧化碳之培養箱中’在加入不同濃度之 P1Ot〇aPlgen〇ne、合成衍生物與活性對照藥物72小時之後,加 1324062 入ΜΤΤ (0.5 mg/ml)染色1小時後,吸除上清液後加入二曱基 亞楓(DMSO),於酵素免疫分析儀(Elisa reader)波長550 nm 下’測定其吸光值(optical density, O.D.)。生物試驗結果如表一 所示’其中IC5〇值代表可抑制50%細胞生長之化合物濃度,並 且以具有毒殺癌症細胞活性的Doxorubicin作為正控制組 (positive control)。 結果 如表一所示,
表一___ 毒殺各細胞株的ICs〇 (pg/mL) 化合物 HepG2 Hep3B MDA-MB-231 MCF-7 protoapigenone 2.32 0.65 0.41 1.07 8a 1.71 0.32 0.18 0.44 8b 10.95 1.45 1.47 2.14 10a 1.34 0.35 0.18 0.93 10b 7.64 0.66 0.54 1.55 15a 1.08 0.09 0.12 0.20 15b 3.16 0.35 0.37 0.86 18a ^ 0.17 0.20 0.13 0.51 Doxorubicin 0.29 0.36 0.08 0.43 A549 3.96 1.33 >20 1.37 1636 0.55 8.20 0.93 0.21 *Doxombicm為活性對照藥物。 如表一所示,在各化合物毒殺癌症細胞株的結果中,與 protoapigenone 及 Doxorubicin 對照,可知化合物 8a,1〇a,15a: 15b與18a對於癌症細胞株具有良好的毒殺效果,尤其對於 Hep3B與MDA-MB-231細胞株’效果更是顯著。由此^驗可 知,以化學方法合成之protoapigenone及其衍生物,與植物中 萃取的protoapigenone相同,都具有對癌症細胞之毒^效果。 根據本發明所揭露之化學合成方法,可產生許多對癌細胞具 毒殺作用的衍生物,並依據這些衍生物的生物活性,進一^開 13 發出更具有療效的化合物,或找出針對特殊癌細胞更有選擇性 的治療方法’使癌症病患的治療更為有效。 細上所述,本案之「用於毒殺癌症細胞的組合物及其合 成方法」*僅可化學絲全合成或半合成產生具有毒殺癌 症細胞的化合物protoapigenone ’更特別的是所述合成方法也 能產生其他具有相似生物活性,甚至活性更強的衍生物。 本發明得由熟習此技藝之人士任施匠思而為諸般修飾, d皆不脫如附申請專利範圍所欲保護者。 ' 【圖式簡單說明】 第一圖係一流程圖, 黃酮類化合物的方法。 第二圖係為化學結構 製備化合物8a,i〇a,i5a及18a。 其係5兒明本發明以全合成方法製備
3,其係說明本發明以半合成方法 第三圖係為化學結構圖, 製備化合物8b,i〇b及15b。 【主要元件符號說明】 無0 14

Claims (1)

1324062 、申請專利範圍:^ -.......-..... ι· 一種用於毒殺癌症細胞的組合物,其包含: 一黃酮類化合物,其結構如式1所示,
其中Β環是4_酮基_2,5_環己二烯基 (4_ox〇_cyd〇hexa-2,5-dienylgr〇up),RrR2 分別選自氫基、經 基及C1-C20烷氧基其中之一,&選自羥基及cl_C2〇烷氧基 其中之一,其中Ri、反2及R3不能同時為羥基。 2·如申請專利範圍第丨項的組合物,其中該黃酮類化合物是自 一化學合成方法而得。 3.如申請專利範圍第2項的組合物’其巾該化學合成方法是以 全合成或半合成方式進行。
4·種用於毋殺癌症細胞的組合物,其包含: 一黃酮類化合物,其結構如式2所/示,
Ο 式2 其中該黃酮類化合物包含一 4-酮基-2,5·環己二烯基 (4-〇x〇-cydohexa-2,5-dienyl group ),& 選自於氫基及 C1-C20 15 丄 院基其中之一。 項的組合物,其中該黃酮類化合物是自 巾該化學合成方法是以 7.-種用於毒殺癌症細胞馳合物,其包含: -黃_化合物,其結構如式3所示,
Ο A 式3 烷基其中l_。 , y gr〇Up ),Rl選自於氫基及C1-C20 little項的組合物,其中該黃鴨化合物是自 物,射槪學合龄法是以 10.—種包含申請專利範圍第丨,4 主 =合物,可用於治療哺乳動二二_化合物 ϋ申4利翻第H)項的醫藥組合物,其中該哺乳動物為人 篡κ Γ 專利耗圍弟1項至第9項中含有B環為4· 步己二烯基的該黃_化合物的方法,其包含以下 將含有兩個第一保護基於4,與6,位置的2,,4,,6,三經基苯乙 16 1324062 酮與一含有一第二保護基的對位瘦基笨 Claisen-Schmidt 縮合反應; 土 甲醛進行 加入一鹵素催化劑; 去除該第二保護基; 加入一氮氧自由基與一 及 高價蛾化合物以進行—氧化反應;以
溶第—保護基,而得到含有該4,基 2,5 己一炸基的該育綱類化合物。 第13項的方法,其中該第—保護基係為曱 氧基曱基(Methoxymethyl,MOMJ。 15=請專利範圍第13 方法,其中該第二保護基係為笨 I6·如申請專利範圍第I3項的方法,其中該齒素催化 ( 專利範ί第13項的方法,其中該氣氧自由基係為 2,2,6,6-四甲基小哌啶氮氧自由基 (2,2,6,6-tetramethylpiperidine-l-oxyl,TEMPO)。 1δ·=ϋίΪ^13項财法,其找高價槪合物係為 一醋k破本或雙三齓乙醯氧蛾化苯。
=·如ΐϊίίί圍第13項的方法,其中該酸溶液係為濃鹽酸。 20.—種合成如申請專利範圍第i項至第9項中含有β環為^ 嗣基-2,5-環己二烯基之該黃酮類化合物的方法,其包^以下 步驟: 、 混^一 B環為對位羥基的黃酮類化合物、一氮氧自由基以及 一高價碘化合物以進行一氧化反應;以及 土 加入一酸溶液,以得到含有該4_酮基_2,5_環己二烯基的該黃 綱類化合物。 21.如申請專利範圍第2〇項的方法,其中該氮氧自由基係為 2,2,6,6-四甲基小哌啶氮氧自由基 (2,2,6,6Αί^ιηβ1ιγ1ρίρ6ΓΪ(ϋι^-1-οχγ^ΤΕΜΡΟ)。 土 17 1324062 22. 如申請專利範圍第20項的方法,其中該高價碘化合物係為二 醋酸碘苯或雙三氟乙醯氧碘化苯。 23. 如申請專利範圍第20項的方法,其中該酸溶液係為濃鹽酸。
18 1324062 < :::: . 、· 一 - X- = - - -· «^· - ' · ' 七、指定代表圖: (一) 本案指定代表圖為:第(一)圖。 (二) 本代表圖之元件符號簡單說明: 本代表圖為流程圖及化學結構,無元件符號。 八、本案若有化學式時,請揭示最能顯示發明特徵的化學 式:
其中 B 環是 4-酮基-2,5-環己二烯基 (4-oxo-cyclohexa-2,5-dienylgroup),分別選自氫基、經 基及C1-C20烷氧基其中之一,R3選自羥基及C1-C20烷氧基 其中之一,其中Ri、R2及R3不能同時為羥基。
TW096112618A 2007-04-10 2007-04-10 Composition for treating cancer cells and synthesis method thereof TWI324062B (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
TW096112618A TWI324062B (en) 2007-04-10 2007-04-10 Composition for treating cancer cells and synthesis method thereof
EP08006865.3A EP1980248B1 (en) 2007-04-10 2008-04-04 Composition for treating cancer cells and synthetic method for the same
HUE08006865A HUE046349T2 (hu) 2007-04-10 2008-04-04 Kompozíciók rákos sejtek kezelésére, és ezek szintézise
KR1020080031721A KR20080092260A (ko) 2007-04-10 2008-04-04 암 세포 치료용 조성물 및 그 합성방법
AU2008201553A AU2008201553B2 (en) 2007-04-10 2008-04-04 Composition for treating cancer cells and synthetic method for the same
JP2008101826A JP5021549B2 (ja) 2007-04-10 2008-04-09 癌細胞の処理のための組成物及びその合成方法
JP2011259177A JP5547167B2 (ja) 2007-04-10 2011-11-28 癌細胞の処理のための組成物及びその合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW096112618A TWI324062B (en) 2007-04-10 2007-04-10 Composition for treating cancer cells and synthesis method thereof

Publications (2)

Publication Number Publication Date
TW200840561A TW200840561A (en) 2008-10-16
TWI324062B true TWI324062B (en) 2010-05-01

Family

ID=39650589

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096112618A TWI324062B (en) 2007-04-10 2007-04-10 Composition for treating cancer cells and synthesis method thereof

Country Status (6)

Country Link
EP (1) EP1980248B1 (zh)
JP (2) JP5021549B2 (zh)
KR (1) KR20080092260A (zh)
AU (1) AU2008201553B2 (zh)
HU (1) HUE046349T2 (zh)
TW (1) TWI324062B (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI486341B (zh) * 2012-05-18 2015-06-01 Univ Kaohsiung Medical 抑制atr與fancd2激活之組成物與方法
US9683008B2 (en) 2010-08-12 2017-06-20 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9918962B2 (en) 2012-05-18 2018-03-20 Kaohsiung Medical University Methods and compositions for inhibition of ATR and FANCD2 activation
US9987291B2 (en) 2007-06-19 2018-06-05 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US10053486B2 (en) 2008-04-25 2018-08-21 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US11413267B2 (en) 2012-05-18 2022-08-16 Kaohsiung Medical University Methods and compositions for inhibition of ATR and FANCD2 activation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9627889B2 (en) 2011-05-12 2017-04-18 Alencon Acquisition Co., Llc. High voltage energy harvesting and conversion renewable energy utility size electric power systems and visual monitoring and control systems
TWI503315B (zh) * 2013-02-07 2015-10-11 Univ China Medical 用於抑制谷胱甘肽S-轉移酶omega 1活性之化合物及其製備方法
EP3081562B1 (en) * 2013-12-09 2018-02-28 China Medical University Compound for inhibiting activity of glutathione s-transferase omega 1 and preparation method thereof, and pharmaceutical compositions containing compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3957795B2 (ja) * 1996-10-04 2007-08-15 興和株式会社 フラボン誘導体及びこれを含有する医薬
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
TWI321052B (en) * 2005-11-08 2010-03-01 Univ Kaohsiung Medical Composition for treating cancer cells and preparation method thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987291B2 (en) 2007-06-19 2018-06-05 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US10053486B2 (en) 2008-04-25 2018-08-21 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US9683008B2 (en) 2010-08-12 2017-06-20 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US10144757B2 (en) 2010-08-12 2018-12-04 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
TWI486341B (zh) * 2012-05-18 2015-06-01 Univ Kaohsiung Medical 抑制atr與fancd2激活之組成物與方法
US9918962B2 (en) 2012-05-18 2018-03-20 Kaohsiung Medical University Methods and compositions for inhibition of ATR and FANCD2 activation
US10195176B2 (en) 2012-05-18 2019-02-05 Kaohsiung Medical University Methods and compositions for inhibition of ATR and FANCD2 activation
US11413267B2 (en) 2012-05-18 2022-08-16 Kaohsiung Medical University Methods and compositions for inhibition of ATR and FANCD2 activation

Also Published As

Publication number Publication date
AU2008201553B2 (en) 2010-06-17
AU2008201553A1 (en) 2008-10-30
KR20080092260A (ko) 2008-10-15
TW200840561A (en) 2008-10-16
JP5021549B2 (ja) 2012-09-12
EP1980248A1 (en) 2008-10-15
JP5547167B2 (ja) 2014-07-09
EP1980248B1 (en) 2019-06-12
HUE046349T2 (hu) 2020-02-28
JP2009023990A (ja) 2009-02-05
JP2012126721A (ja) 2012-07-05

Similar Documents

Publication Publication Date Title
TWI324062B (en) Composition for treating cancer cells and synthesis method thereof
Sisa et al. Photochemistry of flavonoids
CN100503611C (zh) 特定环木脂体的新用途
CN113730391B (zh) 桃金娘酮类化合物在制备抗新型冠状病毒SARS-CoV-2药物中的应用
Du et al. Curcumin analogs as potent aldose reductase inhibitors
JP2006290871A (ja) 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
Wehlauch et al. Investigating biogenetic hypotheses of the Securinega alkaloids: Enantioselective total syntheses of secu’amamine E/ent-virosine A and bubbialine
TW201623208A (zh) 牛樟芝化合物、製備方法及其用途
Singh et al. A Review on a Versatile Molecule: Chalcone.
CN113735814B (zh) 桃金娘酮类化合物及其在制备抗流感病毒药物中的应用
CN101801398A (zh) 认知障碍改善剂
CN113024501B (zh) 具有抗甲型肝炎病毒活性的多甲氧基黄酮衍生物及其制备方法和用途
CN107056739B (zh) Bola型槲皮素衍生物及其制备方法和应用
CN102633796B (zh) 一种苦参酸类衍生物的制备方法
CN108586480A (zh) 含异硫氰酸酯基的青蒿素衍生物及其应用
CN103880678B (zh) 苯甲酸衍生物及其制备与降糖应用
CN111777588B (zh) 假臭草苯丙素类化合物及其应用
Zhou et al. Diverse metabolites from corn silk with anti-Aβ1–42 aggregation activity
KR101333734B1 (ko) 벤조히드록시메톡시칼콘을 유효성분으로 포함하는 항암제 조성물
CN114436884A (zh) 一种牛蒡神经酰胺类化合物及其制备方法和应用
KR100377514B1 (ko) 찰콘 유도체, 그의 제조방법 및 그를 포함하는 약학적조성물
CN106543155B (zh) 作为极光激酶抑制剂的查尔酮及黄酮类衍生物
CN114957272B (zh) 一种色原烷二聚体及其制备方法和应用
Cachet et al. Picrasin K, a new quassinoid from Quassia amara L.(Simaroubaceae)
CN113816857B (zh) 咖啡酰奎宁酸酯类化合物及其制备方法与应用